Influenza, Human  >>  Relenza (zanamivir)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Relenza (zanamivir) / GSK, Vaxart
NCT00989404: Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Completed
1
18
US
Zanamivir
GlaxoSmithKline
Influenza A Virus, H1N1 Subtype
12/09
12/09

Download Options